Study of Vilazodone to Treat Social Anxiety Disorder

Vilazodone in the Treatment of Social Anxiety Disorder: A Double Blind Study

The purpose of this study is to determine whether Vilazodone is effective in the treatment of symptoms of Social Anxiety Disorder among adults.

The proposed study is a 12 week double-blind, placebo-controlled trial in which daily doses of vilazodone 20 to 40 mg/day or matching placebo will be administered on a 1:1 ratio. The study will include 30 outpatients age 18-75 with SAD, generalized subtype who return for at least one post randomization visit where efficacy evaluations are conducted.

Inclusion Criteria:

• Diagnosis of Social Anxiety Disorder, generalized subtype
• LSAS total score of 70 at visits 1 and 2

Exclusion Criteria:

• Lifetime history of Bipolar disorder or Schizophrenia
• Current suicidal risk
• Current unstable medical condition